New pill shows promise against resistant cancers in early trial
NCT ID NCT07514065
First seen Apr 20, 2026 · Last updated May 20, 2026 · Updated 3 times
Summary
This early-phase trial tests a new oral drug, TSL2109, in people with advanced solid tumors, especially metastatic castration-resistant prostate cancer and HR+/HER2- breast cancer. The study aims to find the safest dose and check for early signs of tumor shrinkage. Participants take the drug daily in cycles, and treatment continues as long as it helps and side effects are manageable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Gaobo Cancer Hospital (China Pharmaceutical University)
RECRUITINGShanghai, Shanghai Municipality, 200003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.